178 related articles for article (PubMed ID: 25010594)
1. Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin.
Tzeng TJ; Cao L; Fu Y; Zeng H; Cheng WH
PLoS One; 2014; 9(7):e101664. PubMed ID: 25010594
[TBL] [Abstract][Full Text] [Related]
2. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
Gupta N; Xu Z; El-Sehemy A; Steed H; Fu Y
Gynecol Oncol; 2013 Jul; 130(1):200-6. PubMed ID: 23542683
[TBL] [Abstract][Full Text] [Related]
3. Targeting Werner syndrome protein sensitizes U-2 OS osteosarcoma cells to selenium-induced DNA damage response and necrotic death.
Cheng WH; Wu RT; Wu M; Rocourt CR; Carrillo JA; Song J; Bohr CT; Tzeng TJ
Biochem Biophys Res Commun; 2012 Mar; 420(1):24-8. PubMed ID: 22390926
[TBL] [Abstract][Full Text] [Related]
4. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
Park JT; Chen X; Tropè CG; Davidson B; Shih IeM; Wang TL
Am J Pathol; 2010 Sep; 177(3):1087-94. PubMed ID: 20671266
[TBL] [Abstract][Full Text] [Related]
5. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells.
Hu H; Jiang C; Li G; Lü J
Carcinogenesis; 2005 Aug; 26(8):1374-81. PubMed ID: 15845651
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.
Jiang C; Wang Z; Ganther H; Lü J
Mol Cancer Ther; 2002 Oct; 1(12):1059-66. PubMed ID: 12481429
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
8. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
9. Notch3-specific inhibition using siRNA knockdown or GSI sensitizes paclitaxel-resistant ovarian cancer cells.
Kang H; Jeong JY; Song JY; Kim TH; Kim G; Huh JH; Kwon AY; Jung SG; An HJ
Mol Carcinog; 2016 Jul; 55(7):1196-209. PubMed ID: 26207830
[TBL] [Abstract][Full Text] [Related]
10. Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells.
Qi Y; Schoene NW; Lartey FM; Cheng WH
J Biol Chem; 2010 Oct; 285(43):33010-33017. PubMed ID: 20709753
[TBL] [Abstract][Full Text] [Related]
11. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.
McAuliffe SM; Morgan SL; Wyant GA; Tran LT; Muto KW; Chen YS; Chin KT; Partridge JC; Poole BB; Cheng KH; Daggett J; Cullen K; Kantoff E; Hasselbatt K; Berkowitz J; Muto MG; Berkowitz RS; Aster JC; Matulonis UA; Dinulescu DM
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):E2939-48. PubMed ID: 23019585
[TBL] [Abstract][Full Text] [Related]
12. Persistent p21Cip1 induction mediates G(1) cell cycle arrest by methylseleninic acid in DU145 prostate cancer cells.
Wang Z; Lee HJ; Chai Y; Hu H; Wang L; Zhang Y; Jiang C; Lü J
Curr Cancer Drug Targets; 2010 May; 10(3):307-18. PubMed ID: 20370687
[TBL] [Abstract][Full Text] [Related]
13. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
[TBL] [Abstract][Full Text] [Related]
14. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
15. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
16. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.
Ricciardelli C; Ween MP; Lokman NA; Tan IA; Pyragius CE; Oehler MK
BMC Cancer; 2013 Oct; 13():476. PubMed ID: 24124770
[TBL] [Abstract][Full Text] [Related]
19. Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway.
Zhou H; Zhao H; Liu H; Xu X; Dong X; Zhao E
J BUON; 2018; 23(6):1732-1738. PubMed ID: 30610801
[TBL] [Abstract][Full Text] [Related]
20. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
